All sponsors

TransThera Sciences (Nanjing), Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS2
Open TransThera Sciences (Nanjing), Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
TT-00420 (tinengotinib)
NCT06057571
P2Active, not recruitingCholangiocarcinoma Metastatic502025-07-27 (+1 mo)
FIRST-308
NCT05948475
P3Active, not recruitingCholangiocarcinoma2002026-12 (+7 mo)
Tinengotinib at the optimal dose combined with Fulvestrant
NCT07498478
P2RecruitingBreast Cancer942027-06-30
tinengotinib 10 mg QD plus darolutamide
NCT07871110
P2RecruitingProstate Cancer (CRPC)1822028-12-31
TT-01488 Tablets
NCT07855016
P2Not yet recruitingMantle Cell Lymphoma (MCL)1882029-10-10
TT-00420 (tinengotinib)
NCT07328919
P3Not yet recruitingIntrahepatic Cholangiocarcinoma (Icc); Advanced Cholangiocarcinoma1382029-12-31